A large measurement gap
Cognition is central to health, recovery, performance, and safety, but practical objective measurement is still limited.
Investors
Building the measurement layer for concussion recovery
RT-TRACE is RetinaTek's focused commercial product for objective longitudinal measurement in concussion care, supported by sponsored pilots, a staged FDA strategy, and a broader task-evoked neurocognitive platform.
Concussion recovery is followed through symptoms, brief tests, and clinician judgment, while practical objective longitudinal measurement remains limited. RetinaTek combines task-evoked eye tracking, manual responses, stimulus timing, and research-grade multimodal signals to build a repeatable measurement system for real clinical workflows.
The investment thesis
A differentiated technical approach
RETINA is task-evoked measurement, not passive gaze tracking or a digitized paper test.
A focused concussion-market wedge
RT-TRACE concentrates product development, evidence generation, and customer discovery on specialty concussion recovery programs.
A staged clinical-development path
Paid pilots build evidence now, RT-Focus is the planned first 510(k), and RT-TRACE follows through a condition-specific pathway after appropriate validation.
Platform expansion potential
The same measurement architecture may extend into research endpoints, rehabilitation, cognitive aging, ADHD, MS, CNS trials, defense, occupational safety, and AI/data partnerships through appropriate research, validation, regulatory, and market-development pathways.
A focused market wedge with a staged regulatory path
RT-TRACE focuses commercial development on specialty concussion programs, where repeatable objective recovery measurement addresses a clear workflow problem. Paid research systems and sponsor-funded observational pilots provide a near-term route to revenue, customer learning, and evidence generation without making clinical decision claims.
The regulatory sequence is deliberately narrower at first. RetinaTek has completed an FDA Q-Submission and plans RT-Focus as its first 510(k), establishing a general-assessment, quality, and regulatory foundation before pursuing condition-specific RT-TRACE claims.
Focused wedge: RT-TRACE concussion recovery
- Specialty concussion programs
- Hospital outpatient and sports medicine settings
- Neurology, PM&R, and rehabilitation workflows
- Longitudinal measurement across recovery
- Paid observational pilots alongside usual care
- Claims-disciplined commercial development
- Workflow evidence and customer learning
Long-term upside: regulated and platform markets
- Future RT-TRACE adult and pediatric concussion claims
- ADHD, MS, and adjacent CNS clinical-development pathways after appropriate validation
- Rehabilitation and recovery-tracking research
- CNS biopharma endpoints
- Defense and human performance
- Occupational safety and platform partnerships
Sponsored pilots generate traction. The staged pathway builds toward regulated scale.
Why the staged path matters
Each stage has a distinct job: paid pilots test customer demand and workflow, RT-Focus establishes the first regulatory foundation, and RT-TRACE carries the focused condition-specific market opportunity.
Paid evidence generation now
Research systems and sponsor-funded observational pilots can generate revenue and product evidence before condition-specific clearance.
Real-world deployment learning
Sponsored pilots reveal what works in administration, reporting, training, support, workflow, and repeat testing.
Longitudinal measurement infrastructure
Repeat assessments create experience with cognitive-performance measurement over time, which is central to future recovery-monitoring markets after appropriate validation and clearance.
Customer credibility
Paid concussion-program deployments strengthen conversations with investors, strategic partners, researchers, and clinical-development collaborators.
Product and data operations
Pilot use helps mature the software, data pipeline, quality controls, report design, and service model.
Reduced financing risk
Paid pilot revenue and deployment evidence can reduce execution risk while future indications are validated.
Why now
Eye-tracking hardware has matured
Commercial headset hardware makes controlled, high-quality measurement increasingly deployable.
Concussion recovery remains under-measured
Specialty programs still rely heavily on symptoms, brief tests, and clinician judgment to follow recovery over time.
Specialty clinics need practical longitudinal tools
Concussion, sports medicine, neurology, and rehabilitation programs need objective measures that can fit repeat visits.
CNS trials need better endpoints
Biopharma and academic researchers need repeatable, low-burden digital endpoints for cognitive change and treatment response.
Future recovery monitoring remains under-measured
Concussion and mTBI research and clinical development need objective ways to study recovery trajectory, not just one-time assessment.
AI needs structured labels
Future cognitive-state models need validated, task-evoked labels and longitudinal multimodal datasets.
Why this is not commodity eye tracking
The RetinaTek moat is not the headset. It is the patented task-evoked measurement approach, synchronized multimodal data architecture, scoring and quality-control layer, and evidence base linking these measures to cognitive, clinical, imaging, and performance outcomes.
Patented task-evoked approach
Protected intellectual property around enhanced neuropsychological assessment using eye tracking and cognitive task paradigms.
Federally funded validation
Developed through more than a decade of federally supported military and clinical research.
Multimodal data architecture
Combines eye movements, pupil dynamics, manual responses, and stimulus timing into a unified measurement system.
Proprietary scoring and quality controls
Feature extraction, data-quality logic, score construction, and interpretation models remain proprietary.
Biological and clinical evidence base
Peer-reviewed research supports construct validity, cognitive-load sensitivity, performance-validity utility, and MRI-linked biological plausibility.
Longitudinal data potential
Repeated measurement across research and commercial deployments can create a differentiated dataset for future clinical and platform applications.
Regulated upside: future recovery monitoring, not just diagnosis
Diagnosis is important, but the larger future clinical-development opportunity is repeatable recovery-monitoring: helping determine whether a person is recovering as expected, plateauing, worsening, or likely to benefit from additional evaluation or intervention after appropriate validation and clearance.
RetinaTek is pursuing sponsored and grant-supported validation programs for adult and pediatric concussion/mTBI, with future expansion potential in ADHD, MS, neurodegenerative conditions, rehabilitation, and other CNS markets after appropriate validation and market development. Future clinical claims require appropriate validation and regulatory clearance.
Adult and pediatric concussion/mTBI
RT-TRACE is the initial condition-specific focus for longitudinal recovery measurement after appropriate validation and clearance.
ADHD and attention-related pathways
Potential future clinical-development applications where objective attention, inhibition, and consistency measures may add value.
MS and cognitive fatigue
Potential future clinical-development work involving processing speed, cognitive fatigue, treatment response, and disease-related cognitive change after appropriate validation.
Broader CNS expansion
Future applications may include rehabilitation, neurodegenerative conditions, Long COVID, medication effects, and CNS clinical trial endpoints.
Revenue architecture
Sponsored observational pilots
Paid clinic- and sponsor-funded pilots that generate workflow, usability, and longitudinal evidence alongside usual care.
Research deployments
Paid research systems, endpoint-development studies, clinical-development collaborations, and sponsored validation work.
Future RT-TRACE clinical revenue
Potential per-assessment, subscription, or site-license models for cleared condition-specific use after appropriate validation and clearance.
Strategic and platform partnerships
Potential future opportunities in hardware integrations, CNS endpoints, longitudinal datasets, AI/data partnerships, and international markets.
What new capital unlocks
New capital is intended to move RetinaTek from federally supported science to paid pilot traction, first-clearance execution, and RT-TRACE clinical-development readiness.
RT-Focus 510(k) preparation
Apply completed FDA Q-Submission feedback to the first planned submission and its supporting quality and validation work.
Paid RT-TRACE pilot traction
Generate early revenue, workflow evidence, customer feedback, and longitudinal testing experience in concussion programs.
Research and clinical-development deployments
Expand studies and collaborations using objective neurocognitive endpoints.
Data and software infrastructure
Mature the platform architecture, reporting, data pipeline, security, and longitudinal measurement infrastructure.
Quality and regulatory readiness
Build documentation, usability, risk management, data integrity, and quality controls for future regulated development.
FDA-informed regulatory execution
Translate completed Q-Submission feedback into RT-Focus submission planning and the later condition-specific RT-TRACE pathway.
Adult and pediatric validation strategy
Pursue NIH applications, SBIR submissions, and partner-supported validation programs for future concussion/mTBI recovery-monitoring indications.
Near-term value inflection points
RT-Focus 510(k) plan informed by completed FDA feedback
First paid RT-TRACE sponsored pilots under protocol
Research and clinical-development partnerships
NIH/SBIR submissions and potential awards
Product/software lock for future validation
Quality-system and validation readiness
Longitudinal dataset growth
Strategic platform partnership discussions
Adult and pediatric concussion/mTBI validation launch planning
Investor materials and claims boundaries
RETINA is an in-development neurocognitive measurement platform. RetinaTek has completed an FDA Q-Submission and plans RT-Focus as its first 510(k) submission. RT-TRACE is investigational and is not FDA-cleared or FDA-approved for diagnosis, monitoring, treatment decisions, or return-to-activity decisions. Disease-specific claims require appropriate validation and regulatory clearance.
Interested in RetinaTek's current financing?
RetinaTek is engaging investors who understand medical devices, concussion care, digital health, CNS markets, and regulated software. The company is building sponsored pilot traction while pursuing the larger opportunity: objective, repeatable neurocognitive measurement across clinical and platform markets.